 BEDMER, N.J., Dec. 07, 2020 GLOBE NEWSWIRE -- Matinas BioPharma Holdings, Inc. NYSE AMER: MTNB, a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they plan to collaborate with the National Institute of Allergy and Infectious Diseases NIAID, part of the National Institutes of Health NIH, to test oral formulations of remdesivir in preclinical models. Remdesivir is owned by Gilead Sciences, Inc. Nasdaq: GILD and the lipid nanocrystal LNC platform is owned by Matinas. Any product generated as a part of efforts by Matinas and NIAID would require a license from Gilead for the use of remdesivir and a license from Matinas for the use of the LNC formulation. 